Chemclin Diagnostics Co., Ltd. engages in the research, development, production, and sales of clinical immuno chemiluminescence diagnostic testing reagents and instruments. Its products are LiCA series of diagnostic reagents based on photoexcitation chemiluminescence, and CC series diagnostic reagents and instruments based on enzymatic chemiluminescence. The company's products are used in the detection of infectious diseases such as hepatitis B, C, AIDS, syphilis, hepatitis A, and hepatitis E markers, tumor markers, thyroid hormones, reproductive endocrine hormones, and myocardial markers and inflammation. Chemclin Diagnostics was founded on May 10, 2007and is headquartered in Beijing, China.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company